Rheumatoid Arthritis Market To Reach $90 Billion by 2035

Rheumatoid arthritis market was valued at $54 billion in 2025 and is projected to reach $90 billion by 2035, growing at a CAGR of 5.2% during the forecast period (2026–2035). The rising global burden of autoimmune diseases is significantly strengthening demand for advanced rheumatoid arthritis therapeutics. Rheumatoid arthritis (RA), a chronic inflammatory disorder, continues to increase in prevalence due to aging populations, lifestyle risk factors, and improved diagnostic capabilities. The growing adoption of biologic and targeted synthetic therapies is transforming treatment outcomes and supporting long-term disease management.

Browse the full report description of “Rheumatoid Arthritis Market Size, Share & Trends Analysis Report, By Treatment (Medications, Surgery), By Drug Class (NSAIDs, Corticosteroids, csDMARDs, bDMARDs, tsDMARDs), By Route of Administration (Oral, Injectable), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/rheumatoid-arthritis-market

According to the World Health Organization, approximately 18 million people were living with rheumatoid arthritis globally, with nearly 70% of cases affecting women. Additionally, autoimmune diseases affect over 15 million individuals in the United States alone, accounting for around 4.6% of the population, highlighting the expanding patient pool requiring long-term therapeutic intervention.

Rising Autoimmune Disease Burden Driving Therapeutic Demand

The increasing incidence of autoimmune disorders, combined with improved healthcare access and early diagnosis, is acting as a key macro driver for the rheumatoid arthritis market. Governments and healthcare organizations are focusing on strengthening disease management frameworks and expanding access to advanced biologics and DMARD therapies.

In recent years, public health initiatives have emphasized early-stage diagnosis and intervention to prevent severe joint damage and disability. For instance, national healthcare systems across North America and Europe are integrating rheumatology care into chronic disease management programs, enhancing patient outcomes and increasing treatment adoption rates. Furthermore, increased funding for autoimmune disease research, exceeding $1 billion annually by the U.S. National Institutes of Health, continues to accelerate innovation in targeted therapies and precision medicine approaches.  These developments are directly contributing to the rapid adoption of biologic DMARDs and JAK inhibitors, which offer superior efficacy in controlling disease progression and improving quality of life for patients.

Key Innovation Transforming the Rheumatoid Arthritis Market

The key players in the rheumatoid arthritis market include AbbVie Inc., Johnson & Johnson, Pfizer Inc., Amgen Inc., and Roche, among others. These companies are driving innovation through the development of biologic therapies, biosimilars, and targeted synthetic DMARDs, focusing on improving efficacy, safety, and long-term disease remission outcomes.

• In January 2026, Roche continued to expand its immunology pipeline with next-generation biologics targeting cytokine pathways, aiming to improve treatment outcomes for patients with moderate to severe rheumatoid arthritis.

• In April 2025, AbbVie

These strategic initiatives, including product innovation, pipeline expansion, and biosimilar development, are significantly enhancing competitive dynamics and accelerating market growth.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  o Treatment
  o Drug Class
  o Route of Administration
  o Competitive Landscape – AbbVie Inc., Johnson & Johnson (Janssen), Pfizer Inc., Amgen Inc., Roche (Genentech), among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Rheumatoid Arthritis Market Report Segment

By Treatment

• Medications
• Surgery

By Drug Class

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids
• Conventional Synthetic DMARDs (csDMARDs)
• Biologic DMARDs (bDMARDs)
• Targeted Synthetic DMARDs (tsDMARDs / JAK Inhibitors)

By Route of Administration

• Oral
• Injectable

Global Rheumatoid Arthritis Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/rheumatoid-arthritis-market